Journal article
Prognostic Impact of Total Plasma Cell-free DNA Concentration in Androgen Receptor Pathway Inhibitor–treated Metastatic Castration-resistant Prostate Cancer
H Fettke, EM Kwan, P Bukczynska, N Ng, T Nguyen-Dumont, MC Southey, ID Davis, A Mant, P Parente, C Pezaro, C Hauser, AA Azad
European Urology Focus | ELSEVIER | Published : 2021
Abstract
Total plasma cell-free DNA (cfDNA) levels were recently shown to be prognostic in two large phase III trials of taxane chemotherapy in metastatic castration-resistant prostate cancer (mCRPC). However, whether cfDNA concentration is predictive of treatment outcomes with androgen receptor pathway inhibitors (ARPIs) is unknown. We quantified plasma cfDNA levels at baseline (n = 74) and 4 weeks on treatment (n = 56) in a prospective cohort of mCRPC patients treated with the ARPIs abiraterone acetate or enzalutamide. Elevated total cfDNA concentration (log10) at both baseline (hazard ratio [HR] 5.5, p < 0.001) and week 4 (HR 7.5, p < 0.001) was a significant negative prognostic factor for overall..
View full abstractGrants
Awarded by Astellas Pharma US
Funding Acknowledgements
Heidi Fettke: Australian Government Research Training Program (RTP) Scholarship. Edmond M. Kwan: NHMRC Postgraduate Scholarship, Monash University Postgraduate Publications Award. Melissa Southey: National Health and Medical Research Council (NHMRC, Australia) Senior Research Fellowship (APP1155163). Tu Nguyen-Dumont: National Breast Cancer Foundation (Australia) Career Development Fellowship (ECF-17-001). Ian D. Davis: NHMRC Practitioner Fellowship (APP1102604). Carmel Pezaro: Cancer Council Victoria Early Career Seed Grant. Arun A. Azad: NHMRC Project Grant (GNT1098647), Victorian Cancer Agency Clinical Research Fellowship (CRF14009), and Astellas Investigator-Initiated Grant.